Author: digi

Bioequivalence vs. Biosimilarity in Early Phase Comparisons

June 15, 2025

Bioequivalence vs. Biosimilarity in Early Phase Comparisons Distinguishing Bioequivalence from Biosimilarity in Early Clinical Development Introduction In early clinical development, demonstrating product comparability is critical for both generic small-molecule drugs and biosimilar biologics. While both involve head-to-head assessments with reference products, the scientific and regulatory requirements differ significantly. This article explores the key differences between…

Phase 1 (Safety and Dosage)

Investigators’ Readiness Evaluation Metrics for Clinical Trial Site Initiation

June 15, 2025

digi

Key Metrics to Evaluate Investigator Readiness Before Clinical Trial Initiation Successful clinical trials depend on the preparedness of principal investigators (PIs) and their teams. An investigator’s readiness is a critical factor that determines the quality and compliance of a trial site. Before giving the greenlight for site activation, sponsors and CROs must systematically assess a…

Clinical Research Operations, Site Selection and Initiation

How FSPs Support Scalability in Clinical Trials

June 15, 2025

digi

How FSPs Support Scalability in Clinical Trials How Functional Service Providers (FSPs) Support Scalability in Clinical Trials Scalability is a critical requirement for sponsors managing global clinical trial portfolios. As clinical development programs expand across geographies, therapeutic areas, and study phases, the ability to scale resources and operations efficiently becomes essential. Functional Service Providers (FSPs)…

Contract Research Organizations (CROs), Functional Service Providers (FSPs)

Regulatory Reporting After Site Close-Out Visits in Clinical Trials

June 15, 2025

digi

Regulatory Reporting Requirements After Site Close-Out Visits Once a clinical trial site completes all subject-related activities and the final investigational product (IP) reconciliation, the next critical step is regulatory reporting. This phase ensures that all necessary documentation and notifications are submitted to the appropriate authorities, institutional ethics committees, and trial sponsors to confirm site closure….

Site Close-Out Visits, Site Management and Monitoring

Harmonizing Phase 3 Data Across Regions for Simultaneous Submissions: Ensuring Global Regulatory Success

June 15, 2025

digi

Harmonizing Phase 3 Data Across Regions for Simultaneous Submissions: Ensuring Global Regulatory Success How to Harmonize Data in Phase 3 Trials for Multi-Region Submissions Why Harmonization Matters in Global Phase 3 Trials Phase 3 trials increasingly span multiple countries to meet diverse regulatory expectations, accelerate enrollment, and represent global populations. However, regional differences in data…

Phase 3 (Confirmation and Monitoring)

Ethical Review of Multi-Intervention Trials – Clinical Trial Design and Protocol Development

June 15, 2025

digi

Ethical Review of Multi-Intervention Trials – Clinical Trial Design and Protocol Development “Assessment of Ethics in Multi-Intervention Trials” Introduction to Ethical Review of Multi-Intervention Trials Multi-intervention trials involve the use of more than one intervention in the same study design. This can be highly beneficial as it allows for the comparison of different treatments, combinations…

Clinical Trial Design and Protocol Development, Factorial Designs

Site Readiness Checklists for Clinical Trial Initiation Visits

June 15, 2025

digi

How to Use Site Readiness Checklists for Site Initiation Visits Before any clinical site is activated for patient enrollment, it must demonstrate full operational readiness during the Site Initiation Visit (SIV). A well-designed site readiness checklist serves as a critical quality assurance tool that enables Clinical Research Associates (CRAs), sponsors, and site staff to verify…

Site Initiation Visits, Site Management and Monitoring

The Role of Phase 4 Trials in Biosimilar and Generic Drug Approvals

June 15, 2025

digi

The Role of Phase 4 Trials in Biosimilar and Generic Drug Approvals How Phase 4 Clinical Trials Support Biosimilar and Generic Drug Market Entry and Safety Introduction With rising healthcare costs and the expiration of key patents, biosimilars and generic drugs are becoming vital components of global pharmaceutical strategy. Regulatory authorities now place increasing emphasis…

Phase 4 (Post-Marketing Surveillance)

Preparing a Complete Ethics Committee Submission Package

June 15, 2025

digi

Preparing a Complete Ethics Committee Submission Package How to Prepare a Complete Ethics Committee Submission Package for Clinical Trials Before initiating any clinical trial, obtaining Ethics Committee (EC) or Institutional Review Board (IRB) approval is mandatory. A complete and well-organized EC submission package is critical to secure timely approval and begin site activation. This tutorial…

Ethics Committee Submissions, Informed Consent and Ethics Committees

Impact of Site Engagement on Patient Retention in Clinical Trials

June 15, 2025

digi

Impact of Site Engagement on Patient Retention in Clinical Trials How Site Engagement Directly Affects Patient Retention in Clinical Trials Patient retention is a critical factor in clinical trial success, and research sites play a central role in sustaining participant engagement. The level of commitment, training, communication, and motivation among site staff directly impacts whether…

Patient Recruitment and Retention, Retention Strategies